Dengue vaccines: where are we now and where we are going?
- PMID: 35364020
- DOI: 10.1016/S1473-3099(21)00753-2
Dengue vaccines: where are we now and where we are going?
Conflict of interest statement
We declare no competing interests.
Comment on
-
Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.Lancet Infect Dis. 2022 Jun;22(6):901-911. doi: 10.1016/S1473-3099(21)00706-4. Epub 2022 Mar 29. Lancet Infect Dis. 2022. PMID: 35364022 Clinical Trial.
Similar articles
-
Dengue vaccines: the road to failure or to success?Hum Vaccin Immunother. 2020 Nov 1;16(11):2677-2679. doi: 10.1080/21645515.2020.1733367. Epub 2020 May 19. Hum Vaccin Immunother. 2020. PMID: 32429727 Free PMC article.
-
The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh.Lancet Infect Dis. 2024 Feb;24(2):112-113. doi: 10.1016/S1473-3099(23)00565-0. Epub 2023 Sep 27. Lancet Infect Dis. 2024. PMID: 37776878 Clinical Trial. No abstract available.
-
Safety of Dengue Vaccine?Clin Infect Dis. 2023 Jan 13;76(2):371-372. doi: 10.1093/cid/ciac690. Clin Infect Dis. 2023. PMID: 36048521 Free PMC article. No abstract available.
-
Prospects for a dengue virus vaccine.Nat Rev Microbiol. 2007 Jul;5(7):518-28. doi: 10.1038/nrmicro1690. Nat Rev Microbiol. 2007. PMID: 17558424 Review.
-
Dengue vaccine: a key for prevention.Expert Rev Vaccines. 2020 Jun;19(6):499-506. doi: 10.1080/14760584.2020.1775076. Epub 2020 Jun 16. Expert Rev Vaccines. 2020. PMID: 32452272 Review.
Cited by
-
Recommendations for dengue vaccine implementation in the elderly population.Ther Adv Vaccines Immunother. 2025 Feb 17;13:25151355251321718. doi: 10.1177/25151355251321718. eCollection 2025. Ther Adv Vaccines Immunother. 2025. PMID: 39963378 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical